Jubilant Pharmova Limited performance for Q2’FY27

JUBLPHARMA Jubilant Pharmova Limited – Q2 & H1’FY27 Results Commenting on the Company’s performance for Q2’FY27, Mr. Shyam S Bhartia, Chairman Jubilant Pharmova Limited and Mr. Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova Limited said, “We are pleased to announce revenue of Rs. 2,370 Cr. for Q2’FY27, which reflects a solid growth of 21% on YoY basis. Revenue growth is broad based across all our business segments, but particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new and third line. EBITDA for the quarter stands at Rs. 255 Cr. EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT aadiopharmaceutical products in the Radiopharmaceuticals business. Additionally, margins were impacted by higher operating expenses, including incremental remediation costs at the CMO Montreal facility. Reported PAT for the period stands at Rs. 31 Cr. PAT margins decreased due to lower operating profitability and increase in depreciation